Servier acquires Day One Biopharma

Servier agreed to acquire Day One Biopharma. Reported deal value: $2.5B. Status: Pending. Sector: medical. Target headquarters context: Brisbane, California, United States.

This page summarizes publicly available information about the transaction as of 2026-04-23. Figures and status may change as filings and press coverage update.

Servier, an independent international pharmaceutical group governed by a foundation, today announced the successful completion of the tender offer to acquire all of the issued and outstanding shares of common stock of Day One Biopharmaceuticals, Inc. , a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, for $21.50 per share